Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.9.5231

Nrf2 Overexpression Predicts Prognosis and 5-FU Resistance in Gastric Cancer  

Hu, Xiu-Feng (Department of Oncology, Cancer Research Institute, the First Affiliated Hospital of Henan University of Science and Technology)
Yao, Jun (Department of Oncology, Cancer Research Institute, the First Affiliated Hospital of Henan University of Science and Technology)
Gao, She-Gan (Department of Oncology, Cancer Research Institute, the First Affiliated Hospital of Henan University of Science and Technology)
Wang, Xin-Shuai (Department of Oncology, Cancer Research Institute, the First Affiliated Hospital of Henan University of Science and Technology)
Peng, Xiu-Qing (Department of Oncology, Cancer Research Institute, the First Affiliated Hospital of Henan University of Science and Technology)
Yang, Yan-Tong (Department of Oncology, Cancer Research Institute, the First Affiliated Hospital of Henan University of Science and Technology)
Feng, Xiao-Shan (Department of Oncology, Cancer Research Institute, the First Affiliated Hospital of Henan University of Science and Technology)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.9, 2013 , pp. 5231-5235 More about this Journal
Abstract
Objective: NF-E2-related factor 2 (Nrf2) is activated in several human malignancies. However, the role of Nrf2 in gastric cancer (GC) remains incompletely understood. In this study, we therefore analyzed associations of Nrf2 expression status with clinical features and chemotherapeutic resistance in GC. Materials and Methods: A total of 186 samples from GC patients who underwent gastrectomy were used for prognostic assessment. A further 142 samples from GC cases who received first-line combination chemotherapy were applied for investigation of chemoresistance. The Nrf2 expression was evaluated by immunohistochemistry in GC samples, and its relationship with clinicopathological parameters and chemotherapy sensitivity was analyzed. The effect of Nrf2 gene silencing on chemotherapy resistance was also examined by cell viability assay in vivo. Results: Of the 186 patients with GC, 104/186 (55.9%) showed high expression for Nrf2. The overexpression of Nrf2 was an independent predictor of overall survival [OS, hazard ratio (HR) 3.9; P=0.011] and disease-free survival (DFS, HR 4.3; P=0.002). The gene silencing of Nrf2 reduced resistance to cell death induced by 5-FU in GC cell lines. Conclusion: Our data show that Nrf2 is an independent prognostic factor in GC. Furthermore, Nrf2 confers resistance to chemotherapeutic drug 5-FU in GC cells. Taken together, Nrf2 is a potential prognostic marker and predictive for 5-FU resistance in GC.
Keywords
Gastric cancer; Nrf2; drug resistance; prognosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ajani JA, Moiseyenko VM, Tjulandin S, et al (2007). Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol, 25, 3205-9.   DOI   ScienceOn
2 Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.   DOI   ScienceOn
3 Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD (2008). Dual roles of Nrf2 in cancer. Pharmacol Res, 58, 262-70.   DOI   ScienceOn
4 Huang JY, Xu YY, Sun Z, et al (2012). Comparison different methods of intraoperative and intraperitoneal chemotherapy for patients with gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 13, 4379-85.   DOI   ScienceOn
5 Inoue D, Suzuki T, Mitsuishi Y, et al (2012). Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci, 103, 760-6.   DOI   ScienceOn
6 Jala VR, Radde BN, Haribabu B, Klinge CM (2012). Enhanced expression of G-protein coupled estrogen receptor (GPER/ GPR30) in lung cancer. BMC Cancer, 12, 624.   DOI
7 Ma X, Zhang J, Liu S, et al (2012). Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer. Cancer Chemother Pharmacol, 69, 485-94.   DOI
8 Merikallio H, Pääkkö P, Kinnula VL, Harju T, Soini Y (2012). Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. Hum Pathol, 43, 577-84.   DOI   ScienceOn
9 Shelton P, Jaiswal AK (2013). The transcription factor NF-E2- related factor 2 (Nrf2): a protooncogene? FASEB J, 27, 414-23.   DOI
10 Shibata T, Kokubu A, Saito S, et al (2011). NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia, 13, 864-73.   DOI
11 Singh A, Bodas M, Wakabayashi N, Bunz F, Biswal S (2010). Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid Redox Signal, 13, 1627-37.   DOI   ScienceOn
12 Solis LM, Behrens C, Dong W, et al (2010). Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res, 6, 3743-53.
13 Yamamoto K, Fujiwara Y, Nishida T, et al (2009). Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer. Anticancer Res, 29, 4211-5.
14 Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16.   DOI   ScienceOn
15 Wagner AD, GrotheW, Haerting J, et al (2006). Chemotherapy in advanced gastric cancer: a systematic review and metaanalysis based on aggregate data. J Clin Oncol, 24, 2903-9.   DOI   ScienceOn
16 Wang XJ, Sun Z, Villeneuve NF, et al (2008). Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis, 29, 1235-43.   DOI   ScienceOn
17 Zhang P, Singh A, Yegnasubramanian S, et al (2010). Loss of Kelch-like ECH- associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther, 9, 336-46.   DOI   ScienceOn
18 Yang H, Wang W, Zhang Y, et al (2011). The role of NF-E2- related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer. Clin Lung Cancer, 12, 166-71.   DOI   ScienceOn
19 Yoichiro Mitsuishi, Hozumi Motohashi, Masayuki Yamamoto (2012). The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. Front Oncol, 2, 200.
20 Zhang DD (2010). The Nrf2-Keap1-ARE signaling pathway: The regulation and dual function of Nrf2 in cancer. Antioxid Redox Signal, 13, 1623-6.   DOI   ScienceOn